NYSE:MRKPharmaceuticals
Merck Weighs Revolution Medicines Buyout And Expands AI Oncology Bet
Merck (NYSE:MRK) is reportedly in advanced talks to acquire Revolution Medicines in one of the largest biotech deals in recent years.
The potential acquisition would expand Merck's oncology pipeline, with a focus on targeted cancer therapies.
Merck is also a founding partner in Illumina's new AI driven pharmacogenomics initiative.
Recent collaborations with ChemLex and Guardant Health point to a broader push into AI enabled drug discovery and precision oncology.
For investors, this cluster...